Predictors of Severe COVID-19 in Patients With Diabetes: A Multicenter Review
AuthorKristan, Megan M
Kim, Yoon K
Moxley, Meaghan C
Yip, Terry Cheuk-Fung
JournalEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
MetadataShow full item record
AbstractObjective: Diabetes is an independent risk factor for severe SARS-CoV-2 infections. This study aims to elucidate the risk factors predictive of more severe outcomes in patients with diabetes by comparing the clinical characteristics of those requiring inpatient admissions with those who remain outpatient. Methods: A retrospective review identified 832 patients—631 inpatients and 201 outpatients—with diabetes and a positive SARS-CoV-2 test result between March 1 and June 15, 2020. Comparisons between the outpatient and inpatient cohorts were conducted to identify risk factors associated with severity of disease determined by admission rate and mortality. Previous dipeptidyl peptidase 4 inhibitor use and disease outcomes were analyzed. Results: Risk factors for increased admission included older age (odds ratio [OR], 1.04 [95% CI, 1.01-1.06]; P = .003), the presence of chronic kidney disease (OR, 2.32 [1.26-4.28]; P = .007), and a higher hemoglobin A1c at the time of admission (OR, 1.25 [1.12-1.39]; P < .001). Lower admission rates were seen in those with commercial insurance. Increased mortality was seen in individuals with older age (OR, 1.09 [1.07-1.11]; P < .001), higher body mass index number (OR, 1.04 [1.01-1.07]; P = .003), and higher hemoglobin A1c value at the time of diagnosis of COVID-19 (OR, 1.12 [1.01-1.24]; P = .028) and patients requiring hospitalization. Lower mortality was seen in those with hyperlipidemia. Dipeptidyl peptidase 4 inhibitor use prior to COVID-19 infection was not associated with a decreased hospitalization rate. Conclusion: This retrospective review offers the first analysis of outpatient predictors for admission rate and mortality of COVID-19 in patients with diabetes. © 2021 AACE
Rights/TermsCopyright © 2021 AACE. Published by Elsevier Inc. All rights reserved.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/16264
- Characteristics Associated With Racial/Ethnic Disparities in COVID-19 Outcomes in an Academic Health Care System.
- Authors: Gu T, Mack JA, Salvatore M, Prabhu Sankar S, Valley TS, Singh K, Nallamothu BK, Kheterpal S, Lisabeth L, Fritsche LG, Mukherjee B
- Issue date: 2020 Oct 1
- Lack of association between either outpatient or inpatient glycemic control and COVID-19 illness severity or mortality in patients with diabetes.
- Authors: Mehta PB, Kohn MA, Koliwad SK, Rushakoff RJ
- Issue date: 2021 May
- Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City.
- Authors: Chilimuri S, Sun H, Alemam A, Mantri N, Shehi E, Tejada J, Yugay A, Nayudu SK
- Issue date: 2020 Jul 8
- A Retrospective Study of COVID-19-Related Urgent Medical Visits and Hospitalizations After Outpatient COVID-19 Diagnosis in the US.
- Authors: Wei W, Sivapalasingam S, Mellis S, Geba GP, Jalbert JJ
- Issue date: 2021 Jun
- Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
- Authors: Keitel V, Jensen B, Feldt T, Fischer JC, Bode JG, Matuschek C, Bölke E, Budach W, Plettenberg C, Scheckenbach K, Kindgen-Milles D, Timm J, Müller L, Kolbe H, Stöhr A, Calles C, Hippe A, Verde P, Spinner CD, Schneider J, Wolf T, Kern WV, Nattermann J, Zoufaly A, Ohmann C, Luedde T, RES-Q-HR Trial Team.
- Issue date: 2021 May 17